Tag Archives: FDA and DTC

KEY TAKEAWAY: To suggest that ANY DTC ads are too distracting for fair balance information clearly shows just how out of touch the FDA is with the methods patients make healthcare decisions. Continue reading →

According to the Pink Sheet: The long litany of a prescription drug’s risks in direct-to-consumer television ads could become a thing of the past. FDA plans to conduct a study to determine the impact of limiting risks presented in the ads to those that are serious and actionable while also stating that there are other risks not disclosed in the ad. After viewing the ad, participants will respond to questions about information in the ad to assess their understanding of product risks and benefits; the disclosure about additional risks; product quality; their intention to seek more information about the product; and their perceptions of trust/skepticism regarding product claims and the sponsor.Continue reading →

The US Food and Drug Administration (FDA) will move forward with a survey of healthcare professionals regarding their opinions and perceptions about prescription drug promotion after receiving approval from the Office of Management and Budget (OMB), the executive branch’s regulatory clearing house. While this is a good first step a better idea would have been to conduct a survey with consumers not healthcare professionals as consumers are becoming more involved in every aspect of their healthcare from when the go to see a doctor to what treatments they consider. Continue reading →